Clearside Biomedical (STU:CLM0) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CLM0 Clearside Biomedical Inc STU:CLM0
49 GF Score
Price €4.35
GF Value €110.06
! 7 Warning Signs
View Full Analysis

What is Clearside Biomedical SpecialCharges?

Special Charges only applies to banks.

STU:CLM0
49GF Score
Clearside Biomedical Inc STU:CLM0
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Clearside Biomedical (STU:CLM0) Overvalued in 2026?

Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued. The current stock price of €4.35 is trading 96% below its estimated GF Value™ of €110.06.

Key valuation signals for STU:CLM0:

  • SpecialCharges:
  • GF Value™: €110.06 vs. price of €4.35 (96% below fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the STU:CLM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clearside Biomedical Business Description

Other Exchanges CLSDQ:USA
Address 900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score

Get the complete analysis for STU:CLM0

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.35
Price
€110.06
GF Value